Blood Telomere Length Attrition and Cancer Development in the Normative Aging Study Cohort

DSpace/Manakin Repository

Blood Telomere Length Attrition and Cancer Development in the Normative Aging Study Cohort

Citable link to this page

 

 
Title: Blood Telomere Length Attrition and Cancer Development in the Normative Aging Study Cohort
Author: Hou, Lifang; Joyce, Brian Thomas; Gao, Tao; Liu, Lei; Zheng, Yinan; Penedo, Frank J.; Liu, Siran; Zhang, Wei; Bergan, Raymond; Dai, Qi; Vokonas, Pantel; Hoxha, Mirjam; Schwartz, Joel; Baccarelli, Andrea

Note: Order does not necessarily reflect citation order of authors.

Citation: Hou, L., B. T. Joyce, T. Gao, L. Liu, Y. Zheng, F. J. Penedo, S. Liu, et al. 2015. “Blood Telomere Length Attrition and Cancer Development in the Normative Aging Study Cohort.” EBioMedicine 2 (6): 591-596. doi:10.1016/j.ebiom.2015.04.008. http://dx.doi.org/10.1016/j.ebiom.2015.04.008.
Full Text & Related Files:
Abstract: Background: Accelerated telomere shortening may cause cancer via chromosomal instability, making it a potentially useful biomarker. However, publications on blood telomere length (BTL) and cancer are inconsistent. We prospectively examined BTL measures over time and cancer incidence. Methods: We included 792 Normative Aging Study participants with 1–4 BTL measurements from 1999 to 2012. We used linear mixed-effects models to examine BTL attrition by cancer status (relative to increasing age and decreasing years pre-diagnosis), Cox models for time-dependent associations, and logistic regression for cancer incidence stratified by years between BTL measurement and diagnosis. Findings: Age-related BTL attrition was faster in cancer cases pre-diagnosis than in cancer-free participants (pdifference = 0.017); all participants had similar age-adjusted BTL 8–14 years pre-diagnosis, followed by decelerated attrition in cancer cases resulting in longer BTL three (p = 0.003) and four (p = 0.012) years pre-diagnosis. Longer time-dependent BTL was associated with prostate cancer (HR = 1.79, p = 0.03), and longer BTL measured ≤ 4 years pre-diagnosis with any (OR = 3.27, p < 0.001) and prostate cancers (OR = 6.87, p < 0.001). Interpretation Age-related BTL attrition was faster in cancer cases but their age-adjusted BTL attrition began decelerating as diagnosis approached. This may explain prior inconsistencies and help develop BTL as a cancer detection biomarker.
Published Version: doi:10.1016/j.ebiom.2015.04.008
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535161/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:21459141
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters